A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
In a statement for the record for the House Energy and Commerce Health Subcommittee Committee hearing, Premier underscored how drug shortages threaten the security of the pharmaceutical supply chain, jeopardizing patient care and adding tremendous costs to the healthcare system. The heavy reliance on foreign manufacturing of active pharmaceutical ingredients (API) and raw materials results in downstream drug shortages when a foreign manufacturer fails to meet cGMP or exits the market. In addition, the extent and duration of API or raw material shortages is unknown and results in downstream impact on hoarding and the gray market. Premier urged Committee members to support the bipartisan solutions to address these and other root causes of drug shortages that are contained in the Mitigating Emergency Drug Shortages (MEDS) Act (S. 2723).
Contact: Public_Relations@premierinc.com